Results 221 to 230 of about 389,293 (334)

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett   +20 more
wiley   +1 more source

Effectiveness in the Removal of Endotoxins and Microbiological Profile in Primary Endodontic Infections Using 3 Different Instrumentation Systems: A Randomized Clinical Study [PDF]

open access: bronze, 2017
Daiana Cavalli   +7 more
openalex   +1 more source

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3‐Mutated AML: A FILO‐DATAML‐PETHEMA Real‐World Study

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena   +31 more
wiley   +1 more source

Microbiological water quality monitoring in a resource-limited urban area: a study in Cameroon, Africa [PDF]

open access: gold, 2012
Andrew W. Nelson   +4 more
openalex   +1 more source

Postmortem Microbiology in Forensic Diagnostics: Interpretation of Infectious Causes of Death and Emerging Applications. [PDF]

open access: yesDiagnostics (Basel)
Camatti J   +5 more
europepmc   +1 more source

Microbiological Study of Cigarettes

open access: yesSangyo Igaku, 1967
K. Tarui, Y. Matsuoka, T. Takeuchi
openaire   +2 more sources

Home - About - Disclaimer - Privacy